OMNY Health, a company specializing in helping hospitals monetize operational data, has recently announced a groundbreaking partnership with Scipher Medicine aimed at advancing precision medicine efforts in the field of immunology. The collaboration between these two innovative companies seeks to integrate transcriptomic data from Scipher Medicine with OMNY Health’s extensive electronic health record (EHR) network, which encompasses over 80 million patients.
OMNY Health’s EHR network boasts data from nearly 250,000 patients with rheumatoid arthritis, providing crucial information on key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI, and DAS28. This comprehensive data allows for the thorough tracking of patient outcomes and disease progression, offering valuable insights for healthcare providers and researchers.
Furthermore, through this partnership, OMNY Health’s partners in the life sciences sector will now have access to clinico-transcriptomic datasets of Scipher Medicine’s PrismRA-tested patients. This access to valuable data sets will undoubtedly enhance research and development efforts in precision medicine, particularly in the field of immunology.
The announcement of this partnership comes on the heels of OMNY Health’s launch of the GLP-1 database in 2024, which includes over 600,000 datasets. This database will facilitate clinical research on GLP-1 medications, with a specific focus on pediatrics and social determinants of health, furthering the company’s commitment to advancing healthcare outcomes through targeted therapies and treatments.
Dr. Mitesh Rao, founder and CEO of OMNY Health, expressed his enthusiasm for the collaboration, stating, “Nearly 50 million Americans suffer from autoimmune diseases, and their patient experiences hold valuable insights that, if extracted, could help drive advancements in precision medicine.” This partnership underscores OMNY Health’s dedication to leveraging data and technology to improve healthcare outcomes and enhance patient care.
Dr. Reginald Seeto, president and CEO of Scipher Medicine, emphasized the importance of clinico-transcriptomic data in treatment decisions and personalized medicine. He stated, “Patients deserve clarity and personalized evidence-based answers when navigating individual treatment options. By partnering with OMNY Health, we will enable clinicians and researchers to make data-driven decisions that ultimately reduce the risk to patients.”
This collaboration between OMNY Health and Scipher Medicine highlights the growing trend towards precision medicine and data-driven healthcare solutions. As the healthcare industry continues to embrace innovative technologies and partnerships, patients can expect to benefit from more personalized and effective treatment options in the future.
